Rabbit Recombinant Monoclonal Cytochrome P450 1A2 antibody - conjugated to Alexa Fluor® 594.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
| Application | Reactivity | Dilution info | Notes |
|---|---|---|---|
Application Target Binding Affinity | Reactivity Expected | Dilution info - | Notes - |
Application Antibody Labelling | Reactivity Expected | Dilution info - | Notes - |
Select an associated product type
A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, steroid hormones and vitamins (PubMed:10681376, PubMed:11555828, PubMed:12865317, PubMed:19965576, PubMed:9435160). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:10681376, PubMed:11555828, PubMed:12865317, PubMed:19965576, PubMed:9435160). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:11555828, PubMed:12865317). Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2 (PubMed:11555828, PubMed:12865317). Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis (PubMed:21576599). May act as a major enzyme for all-trans retinoic acid biosynthesis in the liver. Catalyzes two successive oxidative transformation of all-trans retinol to all-trans retinal and then to the active form all-trans retinoic acid (PubMed:10681376). Primarily catalyzes stereoselective epoxidation of the last double bond of polyunsaturated fatty acids (PUFA), displaying a strong preference for the (R,S) stereoisomer (PubMed:19965576). Catalyzes bisallylic hydroxylation and omega-1 hydroxylation of PUFA (PubMed:9435160). May also participate in eicosanoids metabolism by converting hydroperoxide species into oxo metabolites (lipoxygenase-like reaction, NADPH-independent) (PubMed:21068195). Plays a role in the oxidative metabolism of xenobiotics. Catalyzes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin (PubMed:14725854). Metabolizes caffeine via N3-demethylation (Probable).
Cytochrome P450 1A2, CYPIA2, Cholesterol 25-hydroxylase, Cytochrome P(3)450, Cytochrome P450 4, Cytochrome P450-P3, Hydroperoxy icosatetraenoate dehydratase, CYP1A2
Rabbit Recombinant Monoclonal Cytochrome P450 1A2 antibody - conjugated to Alexa Fluor® 594.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 68% PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Cytochrome P450 1A2 often known as CYP1A2 is an important enzyme in the cytochrome P450 superfamily with a known mass around 58 kDa. It is mainly expressed in the liver where it functions in the metabolism of drugs and the bioactivation of various compounds. CYP1A2 also participates in the oxidation of small organic molecules which include xenobiotics and endogenous substrates. Due to its function researchers frequently study CYP1A2 substrates and its inhibitors to understand better its role in drug metabolism and toxicity.
CYP1A2 plays a central role in the oxidative biotransformation of drugs and procarcinogens. It does not form part of a larger complex but interacts dynamically with other enzymes in the detoxification process. CYP1A2 metabolizes several clinical drugs such as caffeine and theophylline and regulates the detoxification of aromatic amines and hydrocarbons. Studying CYP1A2 inhibitors can provide insights into clinically relevant drug interactions and potential side effects in pharmacotherapy.
CYP1A2 functions within the drug metabolism and synthesis of cholesterol steroids and other lipids pathways. In the drug metabolism pathway CYP1A2 works alongside other cytochrome P450 enzymes such as CYP1A1 and CYP1B1 which together ensure the metabolism and clearance of various exogenous and endogenous compounds. These pathways are vital for maintaining drug efficacy and preventing toxicity through the metabolic clearance of pharmaceutical agents and harmful substances.
CYP1A2 activity links to liver disorders and certain cancers. Altered enzyme activity may lead to hepatotoxicity a condition that arises from excessive accumulation of active drug metabolites in the liver. Furthermore due to its role in activating procarcinogens increased CYP1A2 activity relates to a higher risk of developing certain cancers including liver cancer. Researchers often explore these connections to better understand the enzyme's role in disease pathogenesis and to develop CYP1A2-directed therapies.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com